1. APPLICATION OF CELL‐OF‐ORIGIN SUBTYPES DETERMINED BY DIGITAL GENE EXPRESSION IN HIV‐RELATED DIFFUSE LARGE B‐CELL LYMPHOMAS. (June 2017) Authors: Baptista, M.; Tapia, G.; Muñoz‐Marmol, A.; Muncunill, J.; Montoto, S.; Gribben, J.; Calaminici, M.; Martinez, A.; Gonzalez‐Farre, B.; López‐Guillermo, A.; González‐Barca, E.; Terol, M.; Miralles, P.; Alcoceba, M.; Vall‐Llovera, F.; Briones, J.; Abrisqueta, P.; Abella, E.; Provencio, M.; García‐Ba... Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 156 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AUGMENT PHASE III STUDY: LENALIDOMIDE/RITUXIMAB (R2) IMPROVED EFFICACY OVER RITUXIMAB/PLACEBO IN RELAPSED/REFRACTORY FOLLICULAR PATIENTS IRRESPECTIVE OF POD24 STATUS. (12th June 2019) Authors: Leonard, J.; Trneny, M.; Izutsu, K.; Fowler, N.; Hong, X.; Zhang, H.; Offner, F.; Scheliga, A.; Nowakowski, G.; Pinto, A.; Re, F.; Fogliatto, L.; Scheinberg, P.; Flinn, I.; Moreira, C.; Czuczman, M.; Kalambakas, S.; Fustier, P.; Wu, C.; Gribben, J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 114 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. AUGMENT: RELAPSED/REFRACTORY INDOLENT NHL PATIENTS WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO. (12th June 2019) Authors: Gribben, J.; Trneny, M.; Izutsu, K.; Fowler, N.H.; Hong, X.; Zhang, H.; Offner, F.; Scheliga, A.; Nowakowski, G.; Pinto, A.; Re, F.; Fogliatto, L.; Scheinberg, P.; Flinn, I.; Moreira, C.; Czuczman, M.; Kalambakas, S.; Fustier, P.; Wu, C.; Leonard, J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 227 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. LONGITUDINAL ANALYSES OF DIAGNOSTIC‐RELAPSE BIOPSIES OF DIFFUSE LARGE B CELL LYMPHOMA SUGGEST THAT RELAPSE IS MEDIATED BY DISTINCT MECHANISMS IN ABC AND GCB LYMPHOMA. (12th June 2019) Authors: Korfi, K.; Araf, S.; Bewicke‐Copley, F.; Kumar, E.; Cummin, T.; Ashton‐Key, M.; Barrans, S.; Van Hoppe, S.; Burton, C.; Elshiekh, M.; Rule, S.; Crosbie, N.; Clear, A.; Calaminici, M.; Menon, G.; Sha, C.; Bentley, M.; Nagano, A.; Davies, A.; Painter, D. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 142 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. MINIMAL RESIDUAL DISEASE AND OUTCOMES IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) IN THE PHASE III GADOLIN TRIAL OF OBINUTUZUMAB AND BENDAMUSTINE VS BENDAMUSTINE. (June 2017) Authors: Pott, C.; Belada, D.; Danesi, N.; Fingerle‐Rowson, G.R.; Gribben, J.; Harbron, C.G.; Hoster, E.; Kahl, B.S.; Kehden, B.; Mundt, K.E.; Nicolas‐Virelizier, E.; Sehn, L.H.; Cheson, B.D. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 216 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P1411: DUAL EPIGENETIC AND GENETIC EDITING OF PRIMARY HUMAN HAEMATOPOIETIC STEM AND PROGENITOR CELLS. (23rd June 2022) Authors: Saunderson, E.; Encabo, H.; Rouault-Pierre, K.; Piganeau, M.; Bonnet, D.; Gribben, J.; Ficz, G. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1295 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P405: INHIBITION OF CKS1-DEPENDENT PROTEOSTASIS REVEALS VULNERABILITIES IN LEUKAEMIC STEM CELLS WITH CONCOMITANT PROTECTION OF HEALTHY HAEMATOPOIETIC STEM CELLS. (23rd June 2022) Authors: Grey, W.; Rio-Machin, A.; Casado-Izquierdo, P.; Gronroos, E.; Ali, S.; Miettinen, J.; Bewicke-Copley, F.; Parsons, A.; Heckman, C.; Swanton, C.; Cutillas, P.; Gribben, J.; Fitzgibbon, J.; Bonnet, D. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 305 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. POST HOC ANALYSES OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA WHO RECEIVED LENALIDOMIDE PLUS RITUXIMAB (R2) VS RITUXIMAB/PLACEBO (AUGMENT). (12th June 2019) Authors: Thieblemont, C.; Leonard, J.; Trneny, M.; Izutsu, K.; Fowler, N.; Hong, X.; Zhang, H.; Offner, F.; Scheliga, A.; Nowakowski, G.; Pinto, A.; Re, F.; Fogliatto, L.; Scheinberg, P.; Flinn, I.; Moreira, C.; Czuczman, M.; Kalambakas, S.; Fustier, P.; Wu, C. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 226 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. S145: THE COMBINATION OF IBRUTINIB PLUS VENETOCLAX RESULTS IN A HIGH RATE OF MRD NEGATIVITY IN PREVIOUSLY UNTREATED CLL: THE RESULTS OF THE PLANNED INTERIM ANALYSIS OF THE PHASE III NCRI FLAIR TRIAL. (23rd June 2022) Authors: Hillmen, P.; Pitchford, A.; Bloor, A.; Pettitt, A.; Patten, P.; Forconi, F.; Schuh, A.; Fox, C.; Elmusharaf, N.; Gatto, S.; Kennedy, B.; Gribben, J.; Pemberton, N.; Sheehy, O.; Preston, G.; Howard, D.; Hockaday, A.; Cairns, D.; Jackson, S.; Greatorex, N. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 46 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. S206: OBINUTUZUMAB PLUS CHEMOTHERAPY DEMONSTRATES LONG-TERM BENEFIT OVER RITUXIMAB PLUS CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: FINAL ANALYSIS OF THE GALLIUM STUDY. (23rd June 2022) Authors: Townsend, W.; Hiddemann, W.; Buske, C.; Cartron, G.; Cunningham, D.; Dyer, M. J.; Gribben, J.; Phillips, E.; Dreyling, M.; Seymour, J. F.; Grigg, A.; Lin, T.-Y.; Hong, X.-N.; Kingbiel, D.; Nielsen, T. G.; Knapp, A.; Herold, M.; Marcus, R. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗